Literature DB >> 10462574

Identification of MYCN Copy Number Heterogeneity by Direct FISH Analysis of Neuroblastoma Preparations.

.   

Abstract

Background: Amplification of MYCN and deletion of 1p in neuroblastoma are associated wtih a poor prognosis. MYCN copy numbers of 10 or greater are considered to be indicative of poor outcome. However, most molecular genetic methods for estimating the number of MYCN genes do not directly address copy number heterogeneity at the cellular level. Methods and
Results: MYCN copy number was assessed by fluorescence in situ hybridization (FISH), differential polymerase chain reaction (PCR), and Southern blot analysis, using 29 patient tumors. Copy number estimates by PCR or Southern blot analyses identified MYCN amplification in 11 tumors. There was complete concordance between FISH MYCN results in all 11 tumors with amplification. FISH identified 5 tumors with marked heterogeneity for MYCN copy number. Two tumors in which a small percentage of cells within the specimen were amplified would have gone undetected by molecular genetic methods alone. Conclusions: FISH offers the advantage over the other methods of detecting heterogeneity, thereby revealing tumors with small numbers of amplified cells that would otherwise be missed and, in cases of low (3-10) copies of MYCN, distinguishing small numbers of amplified cells (poor prognosis) from triploid tumors (good prognosis). FISH also allows detection of 1p deletion using the same preparations, which represents another advantage. A combination of FISH and conventional molecular methods provides an accurate definition of sample heterogeneity, and should be routinely applied to all neuroblastomas with low levels of MYCN copy number.

Entities:  

Year:  1996        PMID: 10462574     DOI: 10.1054/MODI00100281

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  10 in total

1.  Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Authors:  Kevin Campbell; Arlene Naranjo; Emily Hibbitts; Julie M Gastier-Foster; Rochelle Bagatell; Meredith S Irwin; Hiroyuki Shimada; Michael Hogarty; Julie R Park; Steven G DuBois
Journal:  Eur J Cancer       Date:  2020-05-31       Impact factor: 9.162

Review 2.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

3.  MYCN gene amplification. Identification of cell populations containing double minutes and homogeneously staining regions in neuroblastoma tumors.

Authors:  M Yoshimoto; S R Caminada De Toledo; E M Monteiro Caran; M T de Seixas; M L de Martino Lee; S de Campos Vieira Abib; S M Vianna; S T Schettini; J Anderson Duffles Andrade
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

4.  Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Authors:  A P Berbegall; E Villamón; M Piqueras; I Tadeo; A Djos; P F Ambros; T Martinsson; I M Ambros; A Cañete; V Castel; S Navarro; R Noguera
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

5.  Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses.

Authors:  José Ignacio Martín-Subero; Ilse Chudoba; Lana Harder; Stefan Gesk; Werner Grote; Francisco Javier Novo; María José Calasanz; Reiner Siebert
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization.

Authors:  Ben Beheshti; Ilan Braude; Paula Marrano; Paul Thorner; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

7.  The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.

Authors:  Dominik Bogen; Clemens Brunner; Diana Walder; Andrea Ziegler; Reza Abbasi; Ruth L Ladenstein; Rosa Noguera; Tommy Martinsson; Gabriele Amann; Freimut H Schilling; Marek Ussowicz; Martin Benesch; Peter F Ambros; Inge M Ambros
Journal:  Int J Cancer       Date:  2016-03-22       Impact factor: 7.396

8.  Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.

Authors:  Dinesh Babu Somasundaram; Sheeja Aravindan; Zhongxin Yu; Muralidharan Jayaraman; Ngoc T B Tran; Shibo Li; Terence S Herman; Natarajan Aravindan
Journal:  BMC Cancer       Date:  2019-01-28       Impact factor: 4.430

Review 9.  Molecular biology of neuroblastoma.

Authors:  V Castel; E Grau; R Noguera; F Martínez
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.340

10.  Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.

Authors:  Ana P Berbegall; Dominik Bogen; Ulrike Pötschger; Klaus Beiske; Nick Bown; Valérie Combaret; Raffaella Defferrari; Marta Jeison; Katia Mazzocco; Luigi Varesio; Ales Vicha; Shifra Ash; Victoria Castel; Carole Coze; Ruth Ladenstein; Cormac Owens; Vassilios Papadakis; Ellen Ruud; Gabriele Amann; Angela R Sementa; Samuel Navarro; Peter F Ambros; Rosa Noguera; Inge M Ambros
Journal:  Br J Cancer       Date:  2018-05-14       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.